Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors

BACKGROUND: To evaluate the efficacy and safety of abiraterone acetate (AA) plus prednisone compared with prednisone alone in Asian patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC), and to identify predictive factors. METHODS: We reviewed the medical records o...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Liancheng, Dong, Baijun, Chi, Chenfei, Wang, Yanqing, Gong, Yiming, Sha, Jianjun, Pan, Jiahua, Shangguan, Xun, Huang, Yiran, Zhou, Lixin, Xue, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276197/
https://www.ncbi.nlm.nih.gov/pubmed/30509237
http://dx.doi.org/10.1186/s12894-018-0416-6
_version_ 1783377966209695744
author Fan, Liancheng
Dong, Baijun
Chi, Chenfei
Wang, Yanqing
Gong, Yiming
Sha, Jianjun
Pan, Jiahua
Shangguan, Xun
Huang, Yiran
Zhou, Lixin
Xue, Wei
author_facet Fan, Liancheng
Dong, Baijun
Chi, Chenfei
Wang, Yanqing
Gong, Yiming
Sha, Jianjun
Pan, Jiahua
Shangguan, Xun
Huang, Yiran
Zhou, Lixin
Xue, Wei
author_sort Fan, Liancheng
collection PubMed
description BACKGROUND: To evaluate the efficacy and safety of abiraterone acetate (AA) plus prednisone compared with prednisone alone in Asian patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC), and to identify predictive factors. METHODS: We reviewed the medical records of 60 patients with chemotherapy-naive mCRPC at Renji Hospital who were treated with AA plus prednisone (n = 43) or prednisone alone (n = 17). All patients were assessed for prostate-specific antigen (PSA) response, PSA progression-free survival (PSA PFS), radiographic progression-free survival (rPFS), and overall survival (OS). The ability of several parameters to predict PSA PFS, rPFS, and OS was studied. RESULTS: The median follow-up time was 14.0 months (range 7.0–18.5 months), at which time 19 death events had been reported: 11 in the AA + prednisone group and 8 in the prednisone group. The AA + prednisone group had significantly longer median PSA PFS (10.3 vs 3.0 months, P < 0.001), rPFS (13.9 vs 3.9 months, P < 0.001), and OS (23.3 vs 17.5 months, P = 0.016) than the prednisone-alone group. The most frequently reported grade 3 or 4 adverse event in both the AA + prednisone and prednisone-alone groups was elevated alanine aminotransferase level in 5 of 43 patients (11.6%) and 2 of 17 patients (11.8%), respectively. No adverse events led to discontinuation of therapy. In multivariate analysis, time from androgen deprivation therapy (ADT) to castration resistance of ≤18 months was a determinant of shorter OS (P = 0.007). CONCLUSIONS: These results support the favourable safety and efficacy profile of AA for the treatment of Asian patients with chemotherapy-naive mCRPC. Longer duration of ADT response was significantly associated with longer survival. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12894-018-0416-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6276197
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62761972018-12-06 Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors Fan, Liancheng Dong, Baijun Chi, Chenfei Wang, Yanqing Gong, Yiming Sha, Jianjun Pan, Jiahua Shangguan, Xun Huang, Yiran Zhou, Lixin Xue, Wei BMC Urol Research Article BACKGROUND: To evaluate the efficacy and safety of abiraterone acetate (AA) plus prednisone compared with prednisone alone in Asian patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC), and to identify predictive factors. METHODS: We reviewed the medical records of 60 patients with chemotherapy-naive mCRPC at Renji Hospital who were treated with AA plus prednisone (n = 43) or prednisone alone (n = 17). All patients were assessed for prostate-specific antigen (PSA) response, PSA progression-free survival (PSA PFS), radiographic progression-free survival (rPFS), and overall survival (OS). The ability of several parameters to predict PSA PFS, rPFS, and OS was studied. RESULTS: The median follow-up time was 14.0 months (range 7.0–18.5 months), at which time 19 death events had been reported: 11 in the AA + prednisone group and 8 in the prednisone group. The AA + prednisone group had significantly longer median PSA PFS (10.3 vs 3.0 months, P < 0.001), rPFS (13.9 vs 3.9 months, P < 0.001), and OS (23.3 vs 17.5 months, P = 0.016) than the prednisone-alone group. The most frequently reported grade 3 or 4 adverse event in both the AA + prednisone and prednisone-alone groups was elevated alanine aminotransferase level in 5 of 43 patients (11.6%) and 2 of 17 patients (11.8%), respectively. No adverse events led to discontinuation of therapy. In multivariate analysis, time from androgen deprivation therapy (ADT) to castration resistance of ≤18 months was a determinant of shorter OS (P = 0.007). CONCLUSIONS: These results support the favourable safety and efficacy profile of AA for the treatment of Asian patients with chemotherapy-naive mCRPC. Longer duration of ADT response was significantly associated with longer survival. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12894-018-0416-6) contains supplementary material, which is available to authorized users. BioMed Central 2018-12-03 /pmc/articles/PMC6276197/ /pubmed/30509237 http://dx.doi.org/10.1186/s12894-018-0416-6 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Fan, Liancheng
Dong, Baijun
Chi, Chenfei
Wang, Yanqing
Gong, Yiming
Sha, Jianjun
Pan, Jiahua
Shangguan, Xun
Huang, Yiran
Zhou, Lixin
Xue, Wei
Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors
title Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors
title_full Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors
title_fullStr Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors
title_full_unstemmed Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors
title_short Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors
title_sort abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276197/
https://www.ncbi.nlm.nih.gov/pubmed/30509237
http://dx.doi.org/10.1186/s12894-018-0416-6
work_keys_str_mv AT fanliancheng abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors
AT dongbaijun abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors
AT chichenfei abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors
AT wangyanqing abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors
AT gongyiming abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors
AT shajianjun abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors
AT panjiahua abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors
AT shangguanxun abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors
AT huangyiran abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors
AT zhoulixin abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors
AT xuewei abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors